Related Experiment Video
Updated: Jul 18, 2026
13:45
Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
Leukotriene receptors in atherosclerosis
1Department of Medicine, Karolinska Institutet and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden. Magnus.Back@cmm.ki.se
Annals of Medicine
|November 15, 2006
Summary
Leukotriene receptors in blood vessels promote inflammation and cell accumulation, driving atherosclerosis and restenosis. Targeting these leukotriene receptors offers a potential therapeutic strategy for cardiovascular diseases.
Area of Science:
- Cardiovascular Biology
- Inflammation Research
- Pharmacology
Background:
- Leukotriene-forming enzymes are present in atherosclerotic lesions.
- Locally produced leukotrienes cause inflammation in the vascular wall via BLT and CysLT receptors.
- Leukotriene receptor activation drives inflammatory cell migration and accumulation, contributing to atherosclerosis.
Purpose of the Study:
- To investigate the role of leukotriene receptors in atherosclerosis and restenosis.
- To evaluate leukotriene receptors as potential therapeutic targets for cardiovascular conditions.
Main Methods:
- Analysis of leukotriene-forming enzyme and receptor expression in atherosclerotic lesions.
- Assessment of leukotriene receptor involvement in inflammatory cell behavior within the vascular wall.
- Evaluation of receptor expression on endothelial and vascular smooth muscle cells.
Main Results:
- Leukotriene receptors (BLT, CysLT) are expressed on various cell types within atherosclerotic lesions.
- Leukotriene receptor activation promotes inflammatory cell migration and accumulation.
- Receptors are also found on endothelial and smooth muscle cells, linked to intimal hyperplasia and restenosis.
Conclusions:
- Leukotriene receptors play a significant role in the pathogenesis of atherosclerosis.
- These receptors are implicated in the development of restenotic lesions after angioplasty.
- Leukotriene receptors represent a promising therapeutic target for treating atherosclerosis and preventing restenosis.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:38Inflammation
Overview
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: